Albuminuria Linked to Incident Lung Function Decline
Albuminuria linked to increased risk for COPD and COPD-related events but not asthma
WEDNESDAY, Oct. 10, 2018 (HealthDay News) -- Albuminuria is associated with incident lung function decline and chronic obstructive pulmonary disease (COPD), according to a study published online Sept. 28 in the American Journal of Respiratory and Critical Care Medicine.
Elizabeth C. Oelsner, M.D., from Columbia University in New York City, and colleagues examined whether albuminuria correlated with lung function decline and incident chronic lower respiratory disease in six U.S. population-based cohorts. Albuminuria (urine albumin-to-creatinine ratio) was assessed in spot samples.
The researchers found that among the 10,961 participants with preserved lung function, the mean forced expiratory volume in one second (FEV1) decline was 31.5 mL/year. For each standard decrease in ln-albuminuria, there was a 2.81 percent greater decline in FEV1 and an 11.02 percent greater decline in FEV1/forced vital capacity. There was also a 15 percent increased hazard of incident spirometry-defined moderate-to-severe COPD. Among 14,213 participants followed for events, each standard deviation in ln-albuminuria increased the risk for incident COPD-related hospitalization/mortality by 26 percent. There was no significant association with asthma events. The correlations persisted among those without current smoking, diabetes, hypertension, or cardiovascular disease.
"Albuminuria was associated with greater lung function decline, incident spirometry-defined COPD, and incident COPD-related events in a U.S. population-based sample," the authors write.